Iridex IRIX
Iridex Q2 FY26: revenue $12.6M, down 7%; diluted EPS −$0.07
- Form
- 10-Q
- Filed
- Period
- Importance
- Notable
- Accession
- 0001193125-26-355641
Key figures from this report
These are the numbers Iridex reported for Q2 FY26, the quarter ended Jul 4, 2026, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.
- Revenue$12.6M−7% from $13.6M in Q2 FY2510-Q income statement, on EDGAR
- Net income−$1.3MAgainst −$994K in Q2 FY2510-Q income statement, on EDGAR
- Diluted EPS−$0.07Against −$0.06 in Q2 FY2510-Q income statement, on EDGAR
- Cash and cash equivalents$4.7M−31% from $6.8M in Q2 FY2510-Q balance sheet, on EDGAR
- Cash from operations$174KAgainst −$397K in Q2 FY2510-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters
Similar companies
Companies of similar size in SIC 3845 and related industry codes: the same peer list as the financial tables.
- Nexalin Technology NXL public float $15M, Jun 30, 2025
- Biotricity BTCY public float $13M, Sep 30, 2025
- Beyond Air XAIR public float $16M, Sep 30, 2025
- RetinalGenix Technologies RTGN public float $16M, Jun 30, 2025
- Harvard Apparatus Regenerative Technology HRGN public float $16M, Jun 30, 2025
